Soleno Therapeutics Shares Jump on $2.9 Billion Neurocrine Biosciences Buyout
The acquisition would expand Neurocrine Biosciences’ endocrinology and rare disease portfolio, according to the source.
Summary
No Summary provided as the original text is short
Terms & Concepts
Buyout: An acquisition in which one company purchases another, typically to expand products, research capabilities, or market reach.
Rare disease portfolio: A group of treatments or drug candidates focused on uncommon medical conditions, often a strategic growth area in biotechnology.